Compass Pathways is trading at $11.22 (-4.02%), with broad risk-off pressure the likeliest backdrop; available sources do not establish a direct company-specific trigger. - No fresh company-specific announcement surfaced for October 8; the latest major Phase 3 trial news was announced October 5, not today. - Biotech is down 2.04%. - Riyadh airport attacks drove oil sharply higher and intensified market concerns.